Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

BACKGROUND: We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously‐treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). METHODS: Patients were randomized 2:1 to trabectedin (n = 384) or dacarbazine (n = 193) administered intravenously every 3 weeks. The primar...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer
Auteurs principaux: Patel, Shreyaskumar, von Mehren, Margaret, Reed, Damon R., Kaiser, Pamela, Charlson, John, Ryan, Christopher W., Rushing, Daniel, Livingston, Michael, Singh, Arun, Seth, Rahul, Forscher, Charles, D'Amato, Gina, Chawla, Sant P., McCarthy, Sharon, Wang, George, Parekh, Trilok, Knoblauch, Roland, Hensley, Martee L., Maki, Robert G., Demetri, George D.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6771856/
https://ncbi.nlm.nih.gov/pubmed/31173362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32117
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires